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Background: Depression is up to two to three times as common in people with long-term conditions. It negatively
affects medical management of disease and self-care behaviors, and leads to poorer quality of life and high costs in
primary care. Screening and treatment of depression is increasingly prioritized, but despite initiatives to improve
access and quality of care, depression remains under-detected and under-treated, especially in people with long-
term conditions. Collaborative care is known to positively affect the process and outcome of care for people with
depression and long-term conditions, but its effectiveness outside the USA is still relatively unknown. Furthermore,
collaborative care has yet to be tested in settings that resemble more naturalistic settings that include patient
choice and the usual care providers. The aim of this study was to test the effectiveness of a collaborative-care
intervention, for people with depression and diabetes/coronary heart disease in National Health Service (NHS)
primary care, in which low-intensity psychological treatment services are delivered by the usual care provider -
Increasing Access to Psychological Therapies (IAPT) services. The study also aimed to evaluate the cost-effectiveness
of the intervention over 6 months, and to assess qualitatively the extent to which collaborative care was
implemented in the intervention general practices.
Methods: This is a cluster randomized controlled trial of 30 general practices allocated to either collaborative care
or usual care. Fifteen patients per practice will be recruited after a screening exercise to detect patients with
recognized depression (≥10 on the nine-symptom Patient Health Questionnaire; PHQ-9). Patients in the
collaborative-care arm with recognized depression will be offered a choice of evidence-based low-intensity
psychological treatments based on cognitive and behavioral approaches. Patients will be case managed by
psychological well-being practitioners employed by IAPT in partnership with a practice nurse and/or general
practitioner. The primary outcome will be change in depressive symptoms at 6 months on the 90-item Symptoms
Checklist (SCL-90). Secondary outcomes include change in health status, self-care behaviors, and self-efficacy. A
qualitative process evaluation will be undertaken with patients and health practitioners to gauge the extent to
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access to and quality of care of co-morbid depression of varying intensity in people with diabetes/coronary heart
disease. Additionally, by working with usual care providers such as IAPT, and by identifying and evaluating
interventions that are effective and appropriate for routine use in the NHS, the COINCIDE trial offers opportunities
to address translational gaps between research and implementation.
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Depression is a major global public health challenge.
Lifetime prevalence is between 2 and 15% [1], and by
2030 depressive disorders are predicted to be the second
leading cause of disease burden and disability worldwide
[2]. People with chronic physical illness or long-term
conditions (LTCs) are two to three times more likely to
have depression than healthy controls [3]. When present
with other chronic diseases, depression is associated with
significantly greater reductions in health status compared
with depression alone, or with single or multiple chronic
diseases alone [3].
The presence of physical disease also complicates de-
tection and diagnosis of depression, and can lead to
poorer treatment response in people with major depres-
sive disorder [4]. The presence of depression might also
account for poorer compliance with medical manage-
ment of physical disease [5], leading to poorer health
status and higher costs in primary care [6]. The health-
care costs attributed to untreated depression are high,
and the economic burden of depression is increased in
the presence of co-morbidity [7].
Screening and treatment of depression is increasingly
prioritized. In the UK National Health Service (NHS), the
Quality and Outcomes Framework (QOF) of the general
medical services contract has, since 2006, provided incen-
tives to general practitioners (GPs) to screen for depression
in people with diabetes and coronary heart disease (CHD)
[8]. Additionally, the National Institute for Health and
Clinical Excellence (NICE) has published guidelines that
incorporate stepped-care models to facilitate the delivery
of accessible and effective forms of psychotherapy and
anti-depressant treatment of depression in adults [9], in-
cluding adults with LTCs [10]. Furthermore, the NHS is
significantly resourced to improve access to routine, evi-
dence-based, first-line treatment of common mental-health
problems for adults of working age by rolling out the
Increasing Access to Psychological Therapies (IAPT) pro-
gram across England.
However, depression remains under-detected and
under-treated [11]. Detection rates of depression by
non-psychiatric doctors are generally low [12], and onlya minority of patients with LTCs attending primary care
present with a psychological problem [13]. In the UK,
even where case-finding for depression attracts incen-
tives through the QOF, rates of treatment for depression
are lower in patients with medical co-morbidity than in
those without such conditions [14].
Patients’ tendency to use normalizing attributional styles
that see depression as a normal consequence of ill health,
along with professionals’ conceptualizations of depression
as justifiable and difficult to manage, especially in older
adults, are possible reasons for the under-detection and
problems initiating treatment of depression in primary
care [15,16]. Less is known about barriers to detection and
management of depression care in people with LTCs.
However, barriers to optimal depression care for people
with LTCs can partly be explained by the time-limited na-
ture of primary care, in which clinical decision-making is
often centered around prioritizing competing patient
demands. This is especially true in health settings such as
the NHS, where the management of LTCs is driven by
guidelines and treatment algorithms that focus on single
diseases. In these time-limited and highly structured envir-
onments, competing demands on the time of health pro-
fessionals often lead to prioritization of physical health
problems [17,18], and patients are similarly predisposed to
focus on their physical rather than mental-health pro-
blems [19]. Additionally, a lack of congruence between the
conceptual language used for depression by patients and
professionals, along with deficits in communication skills
on the part of both groups, can lead to uncertainty about
the nature of the problem and reduce opportunities to de-
velop appropriate treatment strategies [18].
There has been a growing emphasis on the role of
educational and organizational interventions to over-
come barriers to managing depression in primary care
[20]. However, simple educational strategies that focus
on guideline implementation are largely ineffective com-
pared with more complex interventions that combine
clinician education with enhanced roles for non-medical
specialists (case management), and a greater degree
of integration between primary and secondary care
(consultation liaison) [21]. In the USA, successful
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informed by the chronic care model, which empha-
sizes that care improvement is linked to the redesign
of interdependent components in health systems, de-
livery systems, patient and provider relationships, de-
cision support tools, clinical information systems,
community resources and organizational factors, such
as leadership [22].
The core ingredient of interventions that have drawn
on the chronic care model is collaborative care, which
typically involves a multiprofessional approach to care,
structured management plans, scheduled follow-ups,
and enhanced inter-professional communication [23].
Collaborative care is more effective than standard care
at improving depression outcomes over both the short
and long term [24]. Evidence is also accumulating that
collaborative care can improve depression care and out-
comes in patients with LTCs such as diabetes [25]. In
patients with depression who have poorly controlled
diabetes and/or CHD, collaborative care involving nurse
case managers working closely with GPs can signifi-
cantly improve control of both medical disease and
depression [26].
Given the overwhelming weight of evidence in favor of
collaborative care, there have been calls for future work
to focus on translation of research into practice [27,28].
However, it is still relatively uncertain whether collab-
orative care is cost-effective in non-managed healthcare
settings outside of the USA, either for major depressive
disorder [29] or for depression and LTCs [30,31]. There
is also uncertainty about whether collaborative care can
improve access and quality of care for people with de-
pression of varying severity, especially in the presence of
LTCs. There is thus scope for research that addresses
whether collaborative care models can be adapted to
structure and organize the care of co-morbid depression
of varying severity (including mild to moderate) in
people with LTCs. Finally, the cost-effectiveness of col-
laborative care has largely been assessed in the context
of large clinical trials, and long-term benefits may be
contingent on the continued presence of research infra-
structure. There is only modest evidence that quality
improvement programs for depression such as collab-
orative care can improve the process and outcome of
care in more naturalistic, non-academic settings that in-
clude patient choice and the usual care providers [32].
This pragmatic trial therefore aims to test the cost-
effectiveness of collaborative care for depression of vary-
ing severity in people with diabetes and/or CHD in
primary-care settings that resemble naturalistic condi-
tions that include patient choice and the delivery of low-
intensity mental-health services by usual care providers
(that is, IAPT).Methods
Background to the trial
The COINCIDE trial was designed by a multidisciplinary
team at the University of Manchester as part of the
Greater Manchester (GM) Collaboration for Leadership
Applied Health Research and Care (CLAHRC) funded by
the UK National Institute for Health Research (NIHR).
The GM CLAHRC is one of nine CLAHRCs established
by the NIHR in 2008. CLAHRCs are partnerships between
universities and their surrounding NHS organizations (in-
cluding primary care) with a strategic focus on evaluating
new therapeutic and organizational approaches to chronic
disease management, and to support more rapid transla-
tion, adoption, and diffusion of research findings into
improved outcomes for patients across wide geographical
areas. In this sense, CLAHRCs are an innovative model to
fill the second translational gap by identifying and evaluat-
ing interventions that are effective and appropriate for
routine use in the NHS [33].
The twin goals of the GM CLAHRC are to improve
quality of care and support for patient self-management
and to reduce inequalities in health and access to care
for people with vascular disease. Its reach is extensive,
covering inner-city, suburban, and semi-rural districts
with diverse populations, including deprived and affluent
communities, and areas with high and low densities of
black and minority ethnic (BME) groups. The program
also supports activity in implementation science to
translate research findings into practice. This focus on
feasibility and implementation in part underpins the
pragmatic approach adopted in our trial. Compared with
explanatory trials, which impose rigorous restrictions on
study entry and treatment delivery to maximize internal
validity, pragmatic trials look to answer questions about
the overall effectiveness of interventions using popula-
tions, settings, and interventions that resemble those
found in routine care. In this sense, pragmatic trials
are best placed to generate data that can be general-
ized to other contexts and offer opportunities to
evaluate cost-effectiveness.
This study will be a pragmatic cluster randomized
controlled trial (RCT) of effectiveness and cost-
effectiveness of a collaborative-care intervention for im-
proving access and quality of care for depression in
people with diabetes and/or CHD compared with usual
primary care in the UK NHS.
Study design
A previous platform trial of collaborative care that com-
bined individual and cluster randomization showed that the
effects of the intervention were partly mediated by
organizational factors [34]. COINCIDE will therefore use a
cluster design to protect against bias caused by contamin-
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allocated to two alternative arms (Figure 1).
Collaborative care is a complex intervention that
draws on the principles of the chronic care model and
typically encompasses a range of organizational, pro-
fessional, and patient-level interventions. First elabo-
rated on by Katon and colleagues at the University
of Washington to describe mental-health interven-
tions delivered by a patient’s GP and a psychiatrist
[35], collaborative care has since undergone evolution
leading to an intervention involving [36]:
 A multiprofessional approach to patient care
delivered by a GP and at least one other health
professional (for example, a nurse, psychologist,
psychiatrist, or pharmacist);
 A structured patient management plan that
facilitates delivery of evidence-based interventions
(either pharmacological or non-pharmacological);
 Scheduled patient follow-ups on one or more
occasion, either in person or by remote
communication (for example, telephone);
 Enhanced inter-professional communication
between the multiprofessional team who share
responsibility for the care of the depressed patient
(for example, team meetings, case conferences,
supervision).
A key component of collaborative care is the introduc-
tion of a care (or case) manager in primary care. The
case manager acts as the conduit between patients and
professionals in primary and specialist care, and works
as the patient’s supporter to jointly determine problems,
set goals, and action plans, and to offer education and
problem-solving skills as ways to promote better patient
self-care.
Case managers can be employed from a variety of pro-
fessional backgrounds. In the USA, registered nurses
employed by privately insured primary-care cooperatives
have worked as case managers in trials of collaborative
care for people with depression and medical co-morbid-
ity. This model of case management is feasible in set-
tings where nurses are already highly skilled in the
medical management of people with chronic disease and
where there is capacity to integrate other elements of
collaborative care with the delivery of routine primary
care. A similar, potentially sustainable model of nurse-
led collaborative care is being piloted in Australian pri-
mary care for patients with depression and heart disease
or diabetes [31]. In the UK NHS, practice nurses may
also be well placed to case-manage patients with depres-
sion and LTC. Practice nurses are central to routine
chronic disease management, and patients are accus-tomed to nurse-led clinics in primary care. Additionally,
there is some evidence that patients perceive nurses as
more holistic and approachable than other health practi-
tioners, and afford more time to interactional tasks that
emphasize patient-centered healthcare [37].
However, in the UK, primary-care consultations are
time-limited, and clinical activity is highly circumscribed
by the need to meet quality improvement targets set by
the QOF, thereby reducing the opportunities for nurses
to devote time to training and additional tasks associated
with the collaborative care of patients with depression
and LTCs [18]. Additionally, because practice-nurse con-
sultations are very structured and driven by guidelines
and templates, it might be harder to train nurses to take
on additional duties and new ways of working [38,39].
For example, when promoting self-care for patients with
diabetes, primary-care nurses are familiar with trad-
itional didactic health education approaches, but might
find it difficult to give lifestyle counseling that draws on
motivational and behavioral approaches typically used by
mental-health professionals [40]. Moreover, training
primary-care professionals to improve recognition and
outcome of primary-care depression has not proven a
success in UK settings, indicating a need to test consult-
ation liaison models such as collaborative care to im-
prove major depressive disorder in some patients [41].
In the COINCIDE trial, the case managers will be
psychological well-being practitioners (PWPs) who are
graduate psychologists who provide high-volume, low-
intensity psychological interventions based on a cogni-
tive and behavioral model for patients with depression
and anxiety disorders. PWPs are employed by IAPT
teams, who are commissioned in each primary-care trust
(PCT). IAPT was established in 2006 to improve access
to routine, evidence-based, first-line treatment for
adults of working age following calls from Layard [42]
for a new deal for people with depression and anxiety
disorders. As part of the UK government’s commit-
ment to mainstream mental health in England and to
reduce inequities between physical and mental-health
services [43], the scope of IAPT will be broadened to
include a standalone program for children and young
adults, and the development of care models for people
with LTCs, medically unexplained symptoms, and se-
vere mental illness [44].
Training PWPs to become case managers to deliver
collaborative care for people with LTCs and depression
thus not only fits the strategic goals of the NHS and
IAPT, but also meets the needs of the CLAHRC to iden-
tify and evaluate interventions that stand the greatest
chance of implementation in routine settings. As well as
being premised on strategic and pragmatic goals, the de-
cision to train PWPs in this trial also draws on a robust
Figure 1 CONSORT diagram for the COINCIDE study. The patients are divided into the collaborative care (experimental) and the usual primary
care (control) groups.
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orative care is higher in studies in which case managers
have a specific mental-health background [24].
Study setting and sample size
Recruitment of IAPT services
This study will be based in primary care across a geo-
graphical area that includes 13 PCTs in the north west
of England. We will recruit IAPT services that providelow-intensity psychological therapies. All IAPT teams
that fall within the catchment area of the target PCTs
will be eligible for inclusion. Within each IAPT service,
clinical team leaders will nominate PWPs to receive the
training in the new collaborative-care model for people
with depression and diabetes/CHD. The ratio of trained
to untrained PWPs in each IAPT service will vary de-
pending on the size of the team; however, it is estimated
that we will need to train up to two PWPs per IAPT
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clinical trial. Furthermore, in the context of this prag-
matic trial, training multiple therapists protects the trial
from drop-out from PWPs, and allows for more robust
assessment of therapists’ effects. Each IAPT team that is
included in the trial will retain capacity to offer psycho-
logical therapy services to other groups, including
patients referred from general practices that are rando-
mized to the usual care arm.Recruitment and randomization of GP practices
We will recruit 30 general practices, representing ap-
proximately 5% of the total number of practices from
the target areas in the northwest of England. All general
practices that fall within the catchment area of the trial
will be eligible for inclusion. Practices will be allocated
to collaborative care or usual care using a central
randomization service provided by the Clinical Trials
Unit at the Christie NHS Foundation Trust, Manchester,
UK. Randomization will be by minimization based on
practice size and area deprivation using the Index of
Multiple Deprivation [45]. In addition, we will target
areas of the northwest (for example, East Lancashire)
that have a high density of people from BME groups, es-
pecially South Asians. This policy will allow us to enroll
sufficient numbers of patients of South Asian origin to
pilot-test the acceptability of the intervention in this
group. In this trial, participants of South Asian origin
are defined as people born in India, Pakistan, Bangladesh
and Sri Lanka and their descendants, but excluding
those born (or descended from those born) in Nepal,
Bhutan, the Maldives, Tibet, Afghanistan, or the Islamic
Republic of Iran [46].
Recruitment and training will be undertaken in two se-
quential waves. This strategy will allow more flexibility
when recruiting IAPT and general practices and offers
opportunities to: 1) stagger recruitment of IAPT teams
and general practices, and 2) run two separate rounds of
case-finding, thereby concentrating data collection
around fixed periods in the trial calendar, leading to
more feasible project management.Patient recruitment
Sample size
Based on a UK trial of collaborative care for major
depressive disorder [29] we have powered this trial to
detect a standardized effect size of 0.4. If each of the 30
practices (15 in each arm) recruits 15 patients at
baseline (450 in total), the study will have > 80% (81.2%)
power to detect this size of effect at the 5% level of
significance, allowing for an intraclass correlation co-
efficient (ICC) of 0.06 (that was identified in aprevious Phase II trial of collaborative care) and a
20% attrition rate.Inclusion criteria
GP practices will be eligible for inclusion if they hold
and maintain a QOF register of: 1) patients with cor-
onary heart disease (QOF indicator CHD1: secondary
prevention of coronary heart disease) [47]; and 2) all
patients aged 17 years and over with diabetes melli-
tus, which specifies whether the patient has type 1 or
type 2 (QOF indicator DM19: diabetes mellitus) [47].
The QOF does not specify how the diagnosis of dia-
betes/CHD is to be made. For the purposes of the QOF,
a record of the diagnosis is sufficient as evidence of dia-
betes/CHD. The CHD register will include all patients
who have had coronary artery revascularization proce-
dures such as coronary artery bypass grafting and those
with a history of myocardial infarction, but does not
generally include patients with cardiac syndrome X.
The QOF recommends separate coding of type 1 and
type 2 diabetes. Where paper or electronic records fail
to distinguish between the two conditions, the QOF
register codes people diagnosed before the age of 30
years and requiring insulin within 1 year of diagnosis as
having type 1; all other cases are coded type 2. The dia-
betes register generally excludes patients under 16 years
and women with gestational diabetes.
Patients of 18 years or over attending each practice
will be eligible for inclusion if: 1) they are listed on the
QOF registers held by the practice for CHD and/or type
1 or type 2 diabetes mellitus, and 2) they have persistent
depressive symptoms (≥10 on the nine-item Patient
Health Questionnaire; PHQ-9) [48].
To enhance the representatives of the sample and in
keeping with the pragmatic design, we will include
patients with diabetes and/or CHD who are already re-
ceiving anti-depressant medication but still have score of
greater than or equal to 10 on the PHQ-9 at the initial
telephone assessment. Patients who are not currently
engaged in psychotherapy but have received psycho-
therapy in the past will be eligible to join the study.
Unlike previous large trials of collaborative care, we
will also include non-English speaking patients of
South Asian origin whose first language is Gujarati,
Urdu, or Bengali; these languages comprise the most
commonly used among British South Asians in the
northwest of England.
Patients will be excluded if they are aged less than 18
years; they refuse consent; their GP removes them from
the practice diabetes/CHD database; they have severe
and enduring mental disorders (psychosis, or bipolar I
or bipolar II disorder); they have active suicidal thoughts
and intent, and require immediate care from a crisis
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prescription drugs requires clinical intervention.
Screening and recruitment of patients
Patient recruitment is widely regarded as the most chal-
lenging aspect of conducting both individual-patient and
cluster RCTs [49]. Failure to recruit target sample sizes
can lead to costly and lengthy extensions and loss of
power. In primary care, time constraints, GPs forgetting
to recruit, and identification of too few eligible patients
threaten recruitment rates [50]. Furthermore, cluster
trials in health settings are at high risk of selection bias
because of selective recruitment of patients by profes-
sionals who are aware of intervention allocation [51],
and through systematic differences in referral behavior
between the clusters in each arm [34].
To ensure adequate recruitment of patients and to
minimize the risk of selection bias, we will recruit
patients by case-finding of eligible patients with depres-
sion and CHD/diabetes rather than relying on direct GP
referral. Such reliance in mental-health trials has
proven to be too slow and inefficient [52], and recent
individual-patient and cluster trials of collaborative
care in the UK and USA have shown that screening eli-
gible patients for depression is an efficient and accept-
able way to improve recruitment rates. Accordingly, in
partnership with the NIHR Mental Health Research
Network (MHRN), the practice staff will work with
clinical studies officers (CSOs) to compile a mailing
database of all patients on the diabetes/CHD registers
held in each participating general practice. GPs in par-
ticipating practices will then be paid to review this
database to exclude patients that do not meet the trial
inclusion criteria and to remove recently deceased
patients. CSOs will then assign study identification
numbers to each patient on the mailing database, and
in partnership with the CLAHRC team, will send a
study pack to all eligible patients on the database, in-
cluding a study invitation letter, an information sheet, a
consent form, and a request for translation. Reminder
letters and replacement study packs will be sent 3 weeks
later to patients who have not responded to the initial
mailing. Because mail-based recruitment is known to
yield poor returns, non-responders to the reminder
letter will also be telephoned by CSOs [53]. Non-
responders of South Asian origin and those do not
speak English will be telephoned by a member of the
COINCIDE study team proficient in Bengali, Gujarati,
and Urdu, who is blinded to intervention allocation.
After receipt of consent forms, CLAHRC research staff
blinded to the intervention allocation will make an initial
screening appointment with eligible patients. Screening
will be undertaken over the telephone using the PHQ-9.Patients who score greater than or equal to 10 on the
PHQ-9 will be informed that they provisionally meet the
inclusion criteria for entry into the trial; patients who
score less than this will be informed that they are not
eligible for the study.
Scores greater than or equal to 10 on the PHQ-9 are
indicative of major depression [48]. Although using a
more conservative cut-off of greater than or equal to 12
might improve the accuracy of predicting major depres-
sion with the PHQ-9 [54], using the lower cut-off of 10
has two advantages. First, we will be able to make com-
parisons with international studies that have used similar
thresholds for depression. Second, using the lower cut-
off of greater than or equal to 10 allows detection of
sub-threshold depression or ‘diabetes -elated distress’,
which has been identified as a key mediating factor be-
tween depression and glycemic control in diabetes [55].
It could be argued that such levels of distress should be
recognized earlier and managed in people with diabetes.
Administration of the PHQ-9 in person or by telephone
produce similar results, making telephone assessments a
reliable screening method for depression in primary care
[56]. Furthermore, the case-finding ability of the PHQ-9 is
comparable with that of standardized diagnostic clinical
interviews when used in medical settings [57], and is as
good as, if not superior to, the Hospital Anxiety and
Depression Scale when used to screen for depression in
non-psychiatric populations [58].
Remission is common for mild to moderate depres-
sion, and the ability of this trial to detect treatment
effects will be improved if the sample includes only
patients with persistent depressive symptoms. To ex-
clude patients with transient and spontaneously remit-
ting depression research staff blinded to the intervention
allocation will therefore visit patients who scored greater
than or equal to 10 on the initial telephone PHQ-9
screen to undertake a second PHQ-9 screen. Patients
who score greater than or equal to 10 at this second
PHQ screening appointment will then be invited to
complete baseline assessments and enter the trial. The
researcher will tell the participant’s GP about their in-
volvement in the study. Patients who score less than or
equal to 9 at this second screening appointment will be
informed that they do not meet the study inclusion cri-
teria and will be excluded; their GP will be informed by
the research team that they will take no further part in
the study at this stage. A CONSORT flow diagram of the
recruitment and screening strategy is shown in Figure 1.
Researchers blinded to the intervention allocation will
forward the details of those patients who are eligible to
join the trial (those who scored ≥10 on PHQ-9 at the
second screening appointment) to the COINCIDE trial
manager. The trial manager will enter these details onto
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working days of the second screening appointment, the
trial manager will contact the clinical lead of the IAPT
team to pass on contact details of patients in the
collaborative-care arm who have met the inclusion
criteria. PWPs will then contact the patient directly to
set up a first appointment.Intervention design
Collaborative care
PWPs will case-manage people with diabetes and/or
CHD and depression in partnership with the patient’s
GP and a practice nurse. Each patient will receive up to
eight sessions with the PWP over 12 weeks. Sessions can
be conducted in person or by telephone, depending on
patient preference. The first session will be 45 to 60
minutes long, during which the case manager will
complete a detailed biopsychosocial patient assessment;
elicit the patient’s ABC-E (autonomic, behavior, cogni-
tion, environment)) model about diabetes and/or CHD
and links with low mood; briefly educate the patient
about diabetes/CHD and depression; assess risk; and
introduce the treatment manual and develop with the
patient a main problem statement. All other sessions will
be between 30 and 40 minutes in length. During the
second session, patients will select which intervention
they prefer, and active treatment will start during the
third session. Although outcomes in depression scores
are the main focus of this study, treatment manuals have
been designed to incorporate interventions that address
any symptoms of anxiety that may present alongside
depression. This assessment and treatment schedule is
consistent with the delivery of brief psychological ther-
apies in the NHS, where six to eight sessions is a
common treatment length.
A 10 minute collaborative meeting (by telephone or in
person) between the patient and the case manager and a
practice nurse will take place at the end of the second
and eighth sessions. These collaborative meetings will
focus on reviewing patients’ progress with their main
problem statement and goals, reviewing relevant health
outcomes (for example, HbA1c, lipids), and a medication
review. The collaborative meeting at the end of the
eighth session also includes opportunities for the
collaborative-care team to discuss with the patient the
next steps to be taken, either to maintain health gains
or, if the patient’s mood has not improved, to review
medication (for example, change anti-depressant or in-
crease dose) or referral to higher-intensity interventions.
The rationale for these collaborative meetings is to
embed collaborative ways of working into the care of
patients with diabetes/CHD beyond the initial 3-monthtreatment phase, especially in relation to goal-setting
and action planning.
The key principles of the intervention are that it is pa-
tient centered and includes partnership working, pro-
active follow-up, and integrated communication and
care between the patient, a mental-health professional
(PWP), and a GP and/or a practice nurse. The type of
psychological intervention used will be chosen by the
patient and will be goal-orientated to primarily improve
mental heath outcomes. However, the delivery of de-
pression treatments in this population might also sup-
port the management of patients’ physical health, for
example, by giving lifestyle advice about diet and exer-
cise. In this sense, the COINCIDE trial aims to use col-
laborative care as a platform to integrate physical and
mental health care for people with depression and dia-
betes and/or CHD.
Usual care
Patients allocated to the control group will receive their
usual care by their primary-care team. For patients with
diabetes and CHD, usual care includes meeting QOF
clinical indicators as part of the General Medical Ser-
vices and Personal Medical Services [47]. Because this is
a pragmatic trial, patients in the usual care group will
still be eligible to receive anti-depressant treatment and
referral for psychological therapy. However, if patients in
the usual care group are referred to an IAPT team for
psychological therapy they will not receive treatment
from a PWP who has been trained in LTCs as part of
the COINCIDE trial. It is not yet known if collaborative
care delivered in the UK NHS as part of a low-intensity
(or step 2) intervention is any more effective than stand-
ard care for depression in people with LTCs. In this
sense, patients in the usual care group with recognized
depression are not disadvantaged, as they will still have
access to evidence-based treatments.
Additionally, we do not anticipate that participation
in the trial will radically alter care pathways for depres-
sion in the control group. There is solid evidence that
case-finding or screening for depression does not in it-
self lead to improvements in detection and management
of depression by clinicians [59], nor is case-finding for
depression known to be a necessary component of ef-
fective collaborative care interventions for depression.
When used as a mechanism to increase recruitment in a
clinical trial, screening alone is unlikely to affect the
quality of care available to patients with recognized de-
pression, thus preserving the comparison in the trial be-
tween collaborative care and usual care for depression.
We will record all aspects of the patients’ usual care in
the control group, and the follow-up assessments will
be identical to those used in the intervention group.
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An adapted stepped-care approach will be used based on
NICE recommendations for treating depression [9,10].
Where demand exceeds supply, stepped-care models
potentially offer a framework to organize and provide
services in the most efficient and effective way by sup-
porting patients, carers, and practitioners in identifying
and accessing the least restrictive (and least intensive)
but most effective intervention first [20]. If a patient
does not benefit from the intervention initially offered,
or declines an intervention, they should be offered an
appropriate intervention from the next step. In theory,
the stepped-care model should be self-correcting, be-
cause patients can be stepped up when they are not pro-
gressing to agreed targets. Currently, collaborative care
is recommended as a step 3 or high-intensity interven-
tion for depression in cases where the patient also has a
LTC and associated functional impairments. However,
in keeping with previous studies of collaborative care
[25], the COINCIDE trial defines collaborative care as a
health-services intervention to improve the quality and
choice of evidence-based care for depression, rather
than as a therapeutic intervention in itself. In this sense,
collaborative care is an organizational framework that
can facilitate and improve the delivery of all types of
therapeutic interventions.
Following formal review after the fourth and eighth
sessions, if patients have persistent depressive symptoms
(<50% decrease in severity on PHQ-9) then PWPs, in
partnership with the patient and in consultation with
their clinical supervisor, will discuss the most appropri-
ate action(s) from a range of options: 1) change low-
intensity psychological intervention; 2) if patient is not
on antidepressants, ask patient to see GP to discuss this
option; 3) if patient is already on antidepressants then
ask patient to see GP to discuss increase in dose or
change of anti-depressant medication; 4) step up to a
higher-intensity intervention (which will usually be cog-
nitive and behavioral therapy; CBT). Weekly monitoring
between the second and eighth session using tools from
the IAPT minimum dataset will support PWPs in
reviewing the patients’ progress and implementing the
stepped-care algorithm. The local collaborative team
(PWPs, supervisors, and GPs) will be able to consult the
trial clinical team (LG, KL, CCG) about starting, or
adjusting dose, or changing anti-depressant medication,
as we recognize that specific medication expertise may
not be available within the IAPT team.
Where there is concern about risk of self-harm, sui-
cide, neglect, or harm to others, patients will be
stepped up to community mental-health services for
assessment and management. This decision will be
made in collaboration with the local supervisor, withadditional support from the trial clinical team (LG, KL,
CCG) where required.
Intervention components
Guided self-help
The treatment, partly delivered with the aid of a pa-
tient manual and workbook, is based on an individual-
guided self-help program for people with depression
and diabetes/CHD delivered by PWPs in collaboration
with a GP and practice nurse. Guided self-help based
on the principles of CBT is one of a range of low-
intensity psychological interventions recommended by
NICE [9,10] for people with persistent sub-threshold
depressive symptoms and mild to moderate depression
and should include the provision of written materials
of an appropriate reading age (or alternative media to
support access); be supported by a trained practitioner,
who typically facilitates the self-help program and
reviews progress and outcome; and consist of up to six
to eight sessions (in person or by telephone), normally
taking place over 9 to 12 weeks, including follow-up.
In the COINCIDE trial, patients in the collaborative-
care arm will be offered a choice of brief psychological
interventions: behavioral activation (BA), graded expos-
ure, cognitive restructuring, and/or lifestyle changes.
Medication management will also be used to ensure
that patients have the necessary knowledge to make an
informed choice about whether to start an anti-
depressant.
Behavioral activation
BA is premised on the notion that depression is func-
tional, whereby depressive feelings and thoughts stimu-
late avoidant behavior, leading to negative reinforcement
and a reduction in positive reinforcement and in normal
(routine, pleasurable, and necessary) activities. This behav-
ioral model of depression acknowledges that the experience
of being depressed includes bi-directional relationships be-
tween life events and modified reinforcement schedules
and secondary problems such as avoidant coping. The for-
mat adopted in this trial is a four-step BA plan to support
patients to reschedule activities to reintroduce positive
reinforcement, improve thoughts and mood, and reduce
avoidant behaviors. In partnership with PWPs, patients will
draw up and self-monitor activity schedules, and identify
goal-oriented behaviors likely to reinforce anti-depressant
environmental contingencies.
BA is as effective and acceptable as higher-intensity
CBT for the treatment of depression [60]. Moreover,
because it adopts a more parsimonious therapeutic
approach than CBT, it can potentially be delivered by
low-intensity therapists (such as PWPs), leading to op-
portunities for implementation in routine settings [61].
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The initial stages of the intervention involve the
PWPs educating patients about the effects of avoid-
ance and the role of safety behaviors in the mainten-
ance of anxiety, which can in turn lead to withdrawal
and depression. Using the patient’s individual symp-
toms, cognitions and behaviors, the PWPs illustrate
how vicious circles (symptom! catastrophic thought
! fear! avoidance! disability! symptom) maintain
the problem.
Patients are then supported in session to draw up a
graded hierarchy of fear-eliciting situations. These take
the form of a series of behavioral experiments, carried
out between sessions, during which irrational expecta-
tions are challenged. Patients are encouraged to work up
the hierarchy, remaining in these fearful situations until
anxiety has significantly decreased. This process must be
completed several times until minimal anxiety is
experienced before the patient proceeds to the next
step on their hierarchy. A successful exposure interven-
tion results in a reduction in the anxiety response and
increased behavioral tolerance of identified triggers. In
cases where the PWP identifies specific anxious cogni-
tions within the maintenance cycle that are resistant to
exposure, the patient will be helped to consider the evi-
dence for and against these fears and, where appropri-
ate, carry out behavioral experiments between sessions,
during which anxious predictions are examined and
reflected upon. The successful addition of this inter-
vention should result in a cognitive shift, whereby the
patient no longer negatively misinterprets physical
symptoms and no longer engages in avoidance or un-
helpful safety behaviors. Where anxiety symptoms are
longstanding, or complex or specific phobias directly
affect self-management, PWPs will facilitate stepping
up to high-intensity CBT.Cognitive restructuring
Cognitive restructuring is used to identify and challenge
seemingly rational and believable negative thoughts by
reframing them as more accurate and realistic beliefs. In
COINCIDE, patients will use thought diaries and engage
in behavioral experiments to identify situations that trig-
ger negative, often automatic, thought processes, andTable 1 Description and aims of the training
Day Section
1 Introduction to collaborative care and LTCs – an overview of the evid
2 Patient-centered interviewing and promoting change
3 Introduction to psychological interventions for depression and LTCs
4 Delivering behavioral activation and cognitive restructuring for depres
5 Maintaining health, effective liaison, supervision and monitoringwill work with the PWP to challenge these negative
thoughts with more positive and goal-oriented ones.
Lifestyle advice
PWPs will work with patients to help them identify and
implement lifestyle changes to lead a healthier lifestyle,
including addressing sleep habits, diet, exercise, and
relaxation.
Medication management
PWPs will work with the patient to assess whether they
are taking medication as prescribed, address any worries
and concerns about the medication and side-effects,
provide good-quality information about medication to
address concerns, and help to arrange a review of medi-
cation with the GP if this is indicated because of patient
and/or therapist concerns about side-effects and/or
failure to improve.
Training and supervision
Training and supervision of case managers
Case-management training will be delivered by a multi-
disciplinary team of high-intensity and low-intensity
therapists, academic GPs, and consultant psychiatrists,
along with disease specialists in diabetes and CHD.
PWPs will receive an initial 1-week (5-day) training
course that includes classroom sessions and interactive
skills practice, along with video demonstrations of con-
ducting a biopsychosocial patient assessment, formulat-
ing a shared problem statement, and the collaborative
team meeting. PWPs will use a training manual during
the training week (Table 1).
Case managers will receive 1 hour of individual
supervision on a weekly basis from a senior mental-
health practitioner within their IAPT team; this may be
undertaken in person or by telephone, depending on
case manager and supervisor preference and availability.
This supervision will be structured in accordance with
the IAPT PWP case-management supervision guidelines
[62,63]. Using this approach, at each session new cases,
cases with risk, those not improving by the eighth ses-
sion and those with missed sessions (did not attend;
DNA) are routinely discussed; in addition, every case
is reviewed every 4 weeks. The case manager will re-
port the case and include the problem statement,Aim
ence base Understanding diabetes and CHD
Developing shared problem statements and goal-setting
Medication management and lifestyle interventions
sion and LTCs
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order Assessment-7 [GAD-7]) and risk issues, medication,
goals and treatment plan, with the addition of items that
specifically focus on the patient’s LTC: the effect of their
depression on their physical health and self-management,
treatment concordance, progress with diabetes and/or
CHD outcomes (for example, hemoglobin A1c, lipids), and
any additional case-management issues. In addition, case
managers will have fortnightly access to the equivalent of
1 hour of clinical skills supervision, conducted in groups
and facilitated by a senior mental-health practitioner
within their IAPT team, allowing the opportunity for in-
depth discussion and further skill development arising
from specific cases.
PWPs will keep and maintain notes for the patients
they treat using the GP practice computer systems, if
this is acceptable to GPs and practice managers. In
addition, as part of reporting for the trial, PWPs will
keep a monitoring sheet for each patient. This monitor-
ing sheet reports how many sessions patients attended
on average, the delivery mode in which they received
follow-up (in person or by telephone), and what inter-
ventions patients selected.
Train the trainer sessions
After completion of follow-ups, irrespective of outcome,
the COINCIDE training team will offer training in the
collaborative-care model to previously untrained super-
visors and clinical leads from IAPT teams enrolled in
the trial. These ‘train the trainer’ sessions will be given
so that IAPT teams can draw on local expertise to train
and then supervise additional step 2 PWPs in using col-
laborative care for treating depression and diabetes/
CHD. This approach will support IAPT teams to build
capacity to meet demand for low-intensity psychological
interventions from people with diabetes/CHD. This
strategy also partly meets IAPT objectives to roll out
psychological therapy services to people with LTCs [44],
and is consistent with the GM CLAHRCs commitment
to support implementation of research into practice.
Training workshop for practice nurses
A separate half-day workshop will be run for practice
nurses drawn from GP practices randomized to the
collaborative-care group. This workshop will be shared
with PWPs trained in the collaborative-care model and
will focus on delivering integrated care and effective
consultation liaison.
Outcome assessment
Primary outcome
The mental-health needs of people with LTCs have his-
torically been under-recognized and under-served in pri-
mary care, and the main aim of this trial is to improvethe access to and quality of depression care for people
with two exemplar LTCs: diabetes and/or CHD. The
interventions used are designed primarily to improve de-
pression rather than both depression and physical health
outcomes. The primary outcome in this trial is therefore
change in depressive symptoms. However, using low-
intensity psychological interventions, including lifestyle
counseling, to treat depression may also be beneficial for
diabetes/CHD, leading to opportunities for therapeutic
synergies across multiple conditions. Accordingly, we
will also test the effects of collaborative-care interven-
tions on a range of secondary outcomes related to dia-
betes and CHD and self-care.
The 90-item Symptoms Checklist (SCL-90) depression
scale will be used to assess changes in severity of depres-
sive symptoms at 6-months [64]. Response to treatment
is defined as greater than or equal to 40% reduction in
SCL-90 scores [65]. We will also use the PHQ-9 at base-
line and follow-up to measure changes in dichotomous
diagnosis of depression [48].
Secondary outcomes
A number of secondary outcomes will be measured,
using various instruments.
 The five-item EuroQoL (EQ-5D) is a standardized
generic measure of health-related quality of life
(HRQOL), which is suitable for use in people with a
wide range of health conditions, and is
recommended by NICE for economic evaluations in
clinical trials. It can be completed by patients, and
may be used as a postal questionnaire or in
interview [66]. Further, it has proven reliability,
validity, and responsiveness in type 2 diabetes,
suggesting that it can be used for modeling health
outcomes in economic evaluations of interventions
for people with type 2 diabetes [67].
 The World Health Organization Quality of Life brief
measure (WHOQoL-BREF) is a measure of global
QOL, which has been validated in a large
international population for a wide range of illnesses
[68]. The brief measure is a 26-item version of the
100-item WHOQoL measure. QOL is measured
across four domains that have been shown to be
salient: physical, psychological, social, and
environmental. Items are measured using a five-
point Likert-type response; a low score for each item
is indicative of poor QOL. Three items are
negatively phrased and reverse scored. Scores from
each domain are calculated using the mean score for
the items within that domain, and multiplying the
mean score by four, so that scores taken from the
WHOQoL-BREF may be compared and contrasted
with the 100-item WHOQoL measure. Additionally,
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The first item on the questionnaire ‘How would you
rate your quality of life?’ can be interpreted
individually as a measure of patient-reported QOL.
Additionally the total score of the WHOQoL has
been shown to operate effectively as a
unidimensional measure of QOL [69].
 The Diabetes Quality of Life (DQoL) tool measures
both the physical and emotional effects of diabetes
and diabetes treatment using five scales: satisfaction
with treatment; impact of treatment; worry about
the future effects of diabetes; worry about social and
vocational issues; and overall well-being [70].
 The Seattle Angina Questionnaire (SAQ) is a reliable
and predictive tool that measures five clinically
important dimensions of functional status in people
with coronary artery disease [71].
 The seven-item Generalized Anxiety Disorder
(GAD-7) is a self-report scale measuring symptom
severity of GAD over the previous 2 weeks on a
four-point Likert scale with a cut-off of greater than
or equal to 8 [72].
 Self-efficacy: changes in self-efficacy cognitions (that
is, a person’s confidence to produce a desired
outcome) are theorized to lead directly to changes
in self-rated health and thereby influence healthcare
utilization. Validated scales used in the evaluation of
the Expert Patient Program will be used [73].
 Patient self-management behavior will be evaluated
using the Health Education Impact Questionnaire
(heiQ). This 42-item scale measures eight
independent dimensions, including positive and
active engagement in life, health-directed behaviors;
skill and technique acquisition; constructive
attitudes and approaches; self-monitoring and
insight; health-service navigation; social integration
and support; and emotional well-being. The heiQ
has shown preliminary evidence of construct validity
[74].
 The Client Satisfaction Questionnaire (CSQ-8) is an
eight-item self-administered questionnaire collected
at the end of service delivery and scored using a
four-point Likert scale. The CSQ-8 scores range
from 8 to 32, with higher values indicating higher
satisfaction. Scores are correlated with change in
self-reported symptoms as measured by the Client
Checklist, a self-report symptom checklist made up
of items from the SCL-90. The CSQ-8 gives
equivalent results to the CSQ-18, and is shorter and
quicker to complete, lending it a practical advantage
for use in primary care [75].
 Healthcare utilization will be examined using the
Patient Service Utilization questionnaire [29]. The Patient Assessment of Chronic Illness Care
(PACIC-5A) is a patient-centered assessment of
implementation of the chronic care model (CCM),
which focuses on the receipt of patient-centered
care and self-management behavior [76]. In patients
with diabetes, the PACIC was shown to be
associated with increased exercise and receipt of
appropriate laboratory assessments and self-
management counseling [77]. PACIC assessments of
the implementation of CCM have also been shown
to be independently associated with improved self-
management behaviors and patient-centered
outcomes in adults with a wide range of LTCs,
including CHD [78]. The five subscales of the
PACIC are patient activation, delivery system/
practice design, goal-setting/tailoring, problem-
solving/contextual, and follow-up/co-ordination. Six
additional items measure minimal contact behavioral
counseling interventions provided in primary care,
in accordance with the ‘Five As’ construct (assess,
advise, agree, assist and arrange) devised by the
Canadian Task Force on Preventive Health Care and
the US Public Health Service [79,80].
 The ENRICHD Social Support Instrument (ESSI) is
a brief seven-item measure of perceived social
support[81]. The scale contains six social support
items that have been shown to be individually
predictive of poor outcome in patients with cardiac
disease, and one item that assesses partner status.
The scale has acceptable reliability and validity.
 The Sheehan Disability Scale [82] is a brief measure
of disability in carrying out life activities across the
three domains of work, social, and family life.
 The Relationship Scales Questionnaire (RSQ) is a
measure of attachment styles containing 30 short
statements describing interpersonal characteristics
in close relationships to be rated on five-point Likert
scale. Each statement contributes to secure,
dismissing, preoccupied, or fearful attachment
patterns. Scores for each attachment pattern are
derived by taking the mean of items representing
each attachment prototype [83].
Where no validated and translated version exists for
use with South Asian patients who do not speak English,
we will culturally adapt and translate all outcome
assessments [84]. The trial will employ a South Asian
language specialist who will have responsibility for
supporting data collection from Urdu, Bengali, and
Gujarati speakers.
Process evaluation
In addition to primary and secondary outcome mea-
Coventry et al. Trials 2012, 13:139 Page 13 of 20
http://www.trialsjournal.com/content/13/1/139sures, we will include measures of characteristics and
processes that may predict whether depression and med-
ical outcomes improve within particular groups of
patients. Evaluation of predictors of treatment response
will include quantitative assessment of the following.
 Patient demographic characteristics, including age,
gender, ethnicity, and socioeconomic status. These
will be derived from the items used in the General
Practice Assessment Questionnaire [85].
 Patient clinical characteristics, including number,
type, and burden of LTCs assessed by a self-reported
measure of disease burden [86].
 Illness representations, using a modified version of
the Brief Illness Perceptions Questionnaire [87], for
use in people with multiple morbidities.
 Adherence to treatment intervention with PWP
(from contact sheet completed by primary-care
practitioner).
 Contextual practice variables: anti-depressant
prescription rates, and availability and referral to
other mental-health services.
Measure of contamination
It is possible that PWPs trained by CLAHRC might
share knowledge and training about collaborative care
with colleagues not enrolled in the COINCIDE trial,
thereby subverting the study protocol and threatening
the internal validity of the study. However, non-
CLAHRC trained PWPs will not be using collaborative
care for the duration of the trial when they encoun-
ter patients with depression and diabetes/CHD.
Thus, the effects of contamination caused by know-
ledge sharing between PWPs are likely to be min-
imal. We will measure the effect of contamination
between CLAHRC-trained and non-CLAHRC-trained
PWPs by assessing changes in knowledge, attitudes,
and clinical practice between baseline and follow-up,
using previously validated approaches to evaluate
depression training programs [88].
The schedule of assessments is shown in Table 2.
Qualitative process evaluation
Although a considerable evidence base exists for the role
of collaborative care in improving treatment of depres-
sion [89], there is a recognized gap between the efficacy
demonstrated in trials and the implementation of the
intervention in everyday practice [28], with particular
uncertainty around whether the model will effectively
translate to UK healthcare systems [36]. The UK
Medical Research Council has highlighted the need for
process evaluations to understand the problems of inte-
grating interventions into healthcare settings. Gask et al.
[89], in an evaluation of collaborative care fordepression in primary care in the UK, demonstrated the
utility of post-trial interviews of participants, which can
provide additional insight beyond pre-trial expectations
of performance.
We will therefore undertake a separate qualitative
process evaluation to evaluate the extent to which the
collaborative-care model was implemented in the inter-
vention GP practices and IAPT teams. The aims of this
arm of the process evaluation are to explore: the feasi-
bility and acceptability of collaborative care as experi-
enced by both patients and professionals, with a
particular focus on integration of physical and mental
health care; the sustainability of collaborative-care
models beyond the trial; and the feasibility and accept-
ability of implementation.Professional experiences of delivering collaborative care
for depression in long-term conditions
Role congruence, perceived patient acceptability, belief
about patients’ capabilities, and perceived effectiveness
can all have an effect on the attitudes of primary-care
clinicians to treatments and screening [90]. In particular,
we will explore whether collaborative care affects the
attitudes of professionals toward addressing the physical
and mental healthcare needs of people with LTCs in
more integrated ways. Gunn et al. [91] reported that in
their study of depression in primary care, GPs were ei-
ther ‘integrators’ or ‘separators’. Integrators saw physical
and mental health as intrinsically linked, whereas separa-
tors tended to deal with physical and mental health pro-
blems as distinct. This proposed study will examine
whether PWPs trained specifically to address depression
in LTCs are able to achieve an integrated approach, and
whether they perceive the views of patients and other
primary care professionals as congruent with this.Patient experience of collaborative care for depression in
long-term conditions
Patients’ views about their perceptions of integrated ser-
vices and also the integration of their physical and men-
tal health care will also be explored. Evidence suggests
that the professional background of the case manager is
key to the success of collaborative care [24], but it is un-
certain whether this is in part associated with patient
perceptions and expectations about the role of mental-
health professionals compared with physical health spe-
cialists such as practice nurses. Patient perceptions and
observations about the degree of interaction and integra-
tion between professionals will also be explored; for ex-
ample, whether patients perceive that communication
between professionals improved, and whether they re-
port that their conditions were managed in more inte-
grated ways through shared determination of treatment
Table 2 Schedule of assessments
Patient assessments Time point
Screening Baseline 6 months
PHQ-9 X X X
Demographic variables, past medical and psychiatric history X
Current physical illness details (including medication) X
Number and burden of diseases X
RSQ X
Self-efficacy measure X X
SCL-90 depression X X
EQ-5D X X
GAD-7 X X
DQoL X X
SAQ X X
WHOQoL-BREF X X
heiQ X X
ESSI X X
AIPQ X X
SDS X X
Anti-depressant prescription rate and referral to other MHS X
Healthcare utilization (purpose-designed questionnaire) X
PACIC X
CSQ X
Practitioner assessment
Change in KAP X X
Abbreviations: AIPQ, Adapted Illness Perceptions Questionnaire; CSQ, Client Satisfaction Questionnaire; DQoL, Diabetes Quality of Life; ESSI, Enhancing Recovery in
Coronary Heart Disease (ENRICHD) Social Support Instrument; EQ-5D, the five-domain EuroQoL quality of life questionnaire; GAD-7, the seven-item Generalized
Anxiety Disorder questionnaire; heiQ, Health Education Impact Questionnaire; KAP, Change in Knowledge, Attitudes, Practice; MHS, mental-health service;
PACIC, Patient Assessment of Chronic Illness Care; PHQ-9, the nine-item Patient Health Questionnaire; RSQ, Relationship Scales Questionnaire; SAQ, Seattle Angina
Questionnaire; SCL-90, the 90-item Symptoms Checklist; SDS, The Sheehan Disability Scale; WHOQoL-BREF,World Health Organization Quality of Life brief measure.
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ical and mental health problems.
Sustainability beyond the trial
Although collaborative care has been shown to be effect-
ive in managing depression, concerns have been raised
about how these effects endure beyond the research con-
text [32]. The process evaluation will explore how suc-
cessfully the collaborative-care model can be embedded
within NHS primary care, where psychological therapy
services are provided by usual care providers. For ex-
ample, we will capture provider and user perspectives to
address whether GP practices and existing IAPT services
have the capacity to continue working collaboratively,
and whether PWPs are the most appropriate profes-
sional to train as case managers.
The process evaluation will therefore provide data on
both the experience of implementation in practice and the
resulting perceptions about the likelihood of the modelbeing integrated in routine practice. These aims will be
met through semi-structured interviews, which will be
analyzed using normalization process theory (NPT).
Theoretical model: normalization process theory
Process evaluations are rarely guided by theoretical models,
and tend to adopt procedural rather than conceptual
approaches to intervention complexity [92]. Theoretical
models are necessary to understand and predict problems
of integration into practice [92]. This is particularly import-
ant for addressing the execution and realization of inter-
ventions in a pre-existing operational context such as
healthcare settings, where novel interventions must fit into
deeply embedded professional and organizational systems.
NPT will be used to develop the topic guides for inter-
views and provide the framework for analysis. NPT is ex-
plicitly concerned with the workability and sustainability
of complex interventions, focusing on the routinization of
intervention components. NPT asks to what extent novel
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tine practice, making it very consistent with the aim of
CLAHRC to identify how interventions can be effectively
adopted into actual practice. NPT can therefore be used to
address both feasibility of implementation, by recognizing
which components of implementation may pose particular
barriers, and the likelihood of sustainability, by examining
the extent to which the intervention can become inte-
grated within everyday practice.
NPT has been successfully used to guide evaluations
of implementation of depression care in healthcare set-
tings [89,91], but has to date not been used to examine
embedding of depression interventions for patients with
chronic illness. NPT states that implementation can be
understood through four generative mechanisms:
 Coherence: the meaning of the practice to actors
 Cognitive participation: engagement, individually
and collectively, with the practice
 Collective action: interaction with pre-existing or
established processes
 Reflexive monitoring: how the practice is assessed
and understood by the actors.
These constructs will be used to guide the analysis of
qualitative data from both patients and professionals ex-
periencing the intervention.Health economics analysis
The objective of the economic study will be to assess the
relative cost-effectiveness of the training intervention to
improve patient outcomes and/or the costs of health
and social care. The framework of cost-effectiveness and
the cost-effectiveness acceptability analysis will be used.
The perspective of the study will include the viewpoints
of health and social care service providers and patients.
These are thought to be the key actors and thus ap-
proximate a societal perspective. Costs and outcomes
will be discounted at the rate recommended by the UK
Treasury at the time of analysis (currently 3.5%).Outcome measures
The primary outcomes of the economic evaluation will
be the incremental cost-effectiveness ratio (ICER) and
the associated net benefit statistic and probability of
cost-effectiveness derived from the cost-effectiveness ac-
ceptability analysis. The measure of patient outcome for
the economic analysis will be quality-adjusted life years
(QALYs) gained at the end of scheduled follow-up. The
QALYs will be estimated as the length of time from
baseline to end of follow-up, multiplied by the utility of
that period. The utility values of the participants will be
estimated from the EQ-5D health status questionnaire[66] completed at baseline and follow-up assessments,
and the associated published societal utility tariffs.
Costs
The direct costs will include the costs of the training
intervention and the costs of health and social care ser-
vices used from recruitment to the end of the scheduled
follow-up. The direct costs of treatment and subsequent
care will be estimated by summing the costs of each re-
source used as an input to provide health and social
care. For each type of resource, the cost will be esti-
mated as the quantity of that resource used multiplied
by the unit cost specific to that resource. In addition,
previous health and social care costs are known determi-
nants of future costs. Information will be collected from
participants and primary-care records about service use
for the 6 months prior to baseline, and these costs will
be used as a covariate in the economic data analysis.
The analysis of economic data will use an intent-
to-treat approach, and missing data will be imputed.
Missing observations will be assumed to be missing
at random and imputed using multiple imputations.
Censored data due to death or withdrawal for other
reasons will be imputed using survival analysis.
ICERs will be estimated as cost per QALY gained for the
primary and sensitivity analyses. Analysis of covariance
(ANCOVA) will be used to estimate the net costs and
QALYs associated with the training intervention to adjust
for any differences in baseline characteristics of patients or
practices. The cost-effectiveness acceptability analysis will
be generated from the ANCOVA to estimate the probabil-
ity that an intervention is cost-effective [93]. The cost-
effectiveness acceptability analysis will be used to estimate
the probability that an intervention is cost-effective using
ceiling thresholds in the range £0 per QALY gained to
£30000 per QALY gained, in increments of £1000. Boot-
strap estimates of the ICER and net benefit statistic (mean
2.5th to 97.5th percentile), cost-effectiveness plane and cost
acceptability curve will be presented [89,90].
Sensitivity analysis will be used to test the effects of
assumptions and data on the ICER, and results of the
cost-effectiveness acceptability analysis. These will in-
clude testing the effects of varying the discount rate
used, extrapolating the results over longer timeframes,
the unit cost sets used to value resources, the methods
used to impute missing data; and the outcome measure
used in the ICER including 1) severity of depressive
symptoms (SCL-90, PHQ-9), 2) health perceptions
(IPQ), 3) self-management behaviors, and 4) other
measures of health status.
SPSS Statistics (IBM, version 20.0) will be used for
data manipulation and descriptive analysis. Stata 12
(StataCorp, Texas 77845–4512, USA) will be used for
the main statistical analyses, and imputation and
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acceptability analysis [93,94].Analysis
The method of allocation of practices to the collabora-
tive care or control arm will be based on simple
randomization (that is, 50:50 chance) for the first six
practices. Minimization will be used thereafter with 0.7/
0.3 probabilities. For each allocation, the balance score
will be estimated based on thresholds for practice list
size and deprivation, measured using the Index of
Multiple Deprivation.
All analyses will be conducted on an intention-to-treat
basis subject to the availability of data. After data clean-
ing, the preliminary analysis will investigate the pattern
of missing baseline and follow-up data. The effect of the
collaborative-care treatment program on depression out-
comes will be estimated using a multi-level mixed-effects
linear regression model, including a random effect for
practices, and controlling for the following baseline cov-
ariates: patient age, gender, ethnicity, and baseline PHQ-9
score. Given that the continuous outcomes are likely to
have a skewed distribution, bootstrap sampling (a method
free from parametric assumptions) will be used to derive
estimates of error variance for the tests of statistical
significance, using 10,000 samples. Sensitivity analysis will
be carried out to check the implications of different
assumptions about the missing data.Ethics
The study has received ethics approval from the National
Research Ethical Service (NRES) NRES Committee North
West Preston (REC code 11/NW/0742). It will be con-
ducted in accordance with the UK Department of Health
Research Governance Framework in health and social, care
and adhere to the ethical principles of the Helsinki
Declaration [95]. All research staff involved in the con-
duct of the trial will meet the standards laid out in the
ICH Harmonized Tripartite Guideline for Good Clinical
Practice [96].
No patient participant will be offered financial incen-
tives to take part. Professionals invited to take part in
qualitative interviews may be reimbursed for their time.
In addition, all data will be anonymized and secured off
site for a period of at least 5 years in accordance with
the Data Protection Act 1995.
The design of this trial will not disadvantage patients
in either the collaborative-care or control groups. No
treatment is being withheld from patients in the control
group, and patients in this group will still be eligible to
receive evidence-based treatment for depression. After
completion of follow-ups and the ‘train the trainer ses-
sions’, control practices will have access to low-intensitytherapists trained in collaborative care for depression
and LTCs. The design therefore approximates a wait-list
control design, which is ethically more acceptable than a
no-treatment control design.User engagement
Service users will be recruited from voluntary self-help
groups for people with diabetes and/or CHD across
Greater Manchester, and will be involved with key
aspects of the trial, including: 1) the trial steering
committee (TSC); 2) the data analysis stage of the quali-
tative process evaluation; and 3) in ensuring information
disseminated to patients and healthcare professionals
during participant recruitment is relevant, appropriate
and informative. Service users will be provided with
training and support where necessary, and travel costs
and time commitments for attending team meetings will
be reimbursed at a rate commensurate with good clinical
practice in the NHS [97]. Representatives will be advised
that their participation is on a voluntary basis, and will
be assured that any information about the trial fed back
to the team will be confidential.The trial steering committee and the data monitoring and
ethics committee
Independent supervision of the trial will be carried out
by members of the TSC. The TSC will have responsibil-
ity for monitoring progress of the trial, adherence to the
protocol, patient safety, and consideration of new infor-
mation. Membership of the TSC will include the princi-
pal investigator along with an independent chair, and at
least two other independent members. The trial manager
and the trial statistician will attend when appropriate.
An observer from the host institution (University of
Manchester) will be invited to attend the TSC.
The data monitoring committee and ethics committee
(DMEC) will be the only body in the trial with full ac-
cess to unblinded comparative data. Members of the
DMEC will be completely independent from the trial
and the host institution, and will report to the TSC to
determine if there are ethical or safety reasons for the
trial not to continue.Forecast execution dates
The set-up period began in August 2011, and continued
until December 2011. Recruitment of GP practices and
IAPT teams began in January 2012 and continued in
two sequential waves for 6 months. Patient recruitment
started in May 2012 and will continue until January
2013. Follow-up will start in November 2012 and con-
tinue until all patients have been assessed at 6 months.
Data analysis will start in August 2013.
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Developing new systems to deliver care for depression
and for depression plus LTCs remains a significant chal-
lenge for the future. It is still unclear how integrated
care models can be disseminated and implemented in
routine care in settings in which limited resources, pro-
fessional resistance, and competing priorities are signifi-
cant barriers to change, barriers likely to be exacerbated
in these times of economic uncertainty. The COINCIDE
trial aims to train PWPs to deliver the benefits of inte-
grated care to patients with co-morbid depression and
diabetes/CHD. These professionals have the advantage
of an existing knowledge base around the delivery of
evidence-based brief psychological treatments. Our chal-
lenge is to provide them with skills to deliver these treat-
ments, in partnership with primary-care staff, to patients
with LTCs, and to overcome some of the complex inter-
actions between mental and physical health that can stand
in the way of patient change [98]. In addition, by harnes-
sing and enhancing the skills of usual care providers
employed by IAPT services the COINCIDE trial offers a
unique opportunity to establish durable organizational
change in the way in which patients with depression and
LTCs are managed in primary care.
Populations with depression and co-occurring multiple
medical problems rarely get access to collaborative care,
even though the evidence that collaborative care may be
effective in adults with depression and LTCs is accumu-
lating [25]. We anticipate that the results of this trial will
further support the case for delivering collaborative
models of care to patients with common mental-health
problems and LTCs, thus improving access and quality
of mental-health services for under-served groups.
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